Cordis Invests in E2, Developer of VTE Devices

April 5, 2022—Cordis announced a strategic investment in Endovascular Engineering (E2), which is based in Menlo Park, California. The venture expands the scope of the company into the venous thromboembolism (VTE) market.

According to Cordis, E2 is a preclinical stage company developing next-generation mechanical thrombectomy devices to treat patients with deep vein thrombosis (DVT) and pulmonary embolism (PE). The company was founded in 2019 by Luis Savastano, MD. The platform technology was advanced through Dr. Savastano’s partnership with Santé Ventures and Inventure Group.

Cordis is partnering with Santé Ventures and another strategic investor in the E2 transaction.

Duke Rohlen, Executive Chairman of Cordis and CEO of Cordis-X, an independent accelerator created to drive innovation and growth for Cordis, commented in the company’s press release, “Our investment in E2 positions Cordis at the vanguard of innovation in venous interventions. We are proud to support the team's efforts to define a new standard of care for patients suffering from thromboembolism.”

Cordis CEO Shar Matin, added, “Our investment in E2 meets all the criteria in our strategy to fuel differentiated technology development, expanding our portfolio with innovative and clinically compelling solutions that respond to unmet needs in cardiovascular health. Growing our venous offerings expands our capacity to improve outcomes and deliver better quality of life to more patients around the world.”

Mr. Matin continued, “Our new business model leverages the robust global corporate infrastructure and sales capacity of Cordis, and the speed, creativity, and agility of the Cordis-X growth engine. DVT and PE affect patients young and old. The investment in E2 supports Cordis' legacy as a leader in creating lifesaving cardiovascular technologies.”